WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H561215
CAS#: 127464-43-1
Description: Emoxypine Succinate is an antioxidant. It inhibits free radical oxidation of biomembrane lipids and modulates the activity of membrane-bound enzymes and the receptor complexes of the brain membranes.
Hodoodo Cat#: H561215
Name: Emoxypine Succinate
CAS#: 127464-43-1
Chemical Formula: C12H17NO5
Exact Mass: 0.00
Molecular Weight: 255.270
Elemental Analysis: C, 56.46; H, 6.71; N, 5.49; O, 31.34
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: Emoxypine Succinate; Mexidol
IUPAC/Chemical Name: 2-Ethyl-6-methylpyridin-3-ol Succinate
InChi Key: IKMNOGHPKNFPTK-UHFFFAOYSA-N
InChi Code: InChI=1S/C8H11NO.C4H6O4/c1-3-7-8(10)5-4-6(2)9-7;5-3(6)1-2-4(7)8/h4-5,10H,3H2,1-2H3;1-2H2,(H,5,6)(H,7,8)
SMILES Code: OC1=CC=C(C)N=C1CC.O=C(O)CCC(O)=O
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
Biological target: | |
In vitro activity: | |
In vivo activity: |
The following data is based on the product molecular weight 255.27 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
Formulation protocol: | |
In vitro protocol: | |
In vivo protocol: |
1: Lyang OV, Kochetov AG. [The use of mexidol in chronic cerebral ischemia]. Zh Nevrol Psikhiatr Im S S Korsakova. 2013;113(12):126-9. Review. Russian. PubMed PMID: 24596977.
2: Voronina TA. [Mexidol: the spectrum of pharmacological effects]. Zh Nevrol Psikhiatr Im S S Korsakova. 2012;112(12):86-90. Review. Russian. PubMed PMID: 23461005.
3: Çakici N, Fakkel TM, van Neck JW, Verhagen AP, Coert JH. Systematic review of treatments for diabetic peripheral neuropathy. Diabet Med. 2016 Nov;33(11):1466-1476. doi: 10.1111/dme.13083. Epub 2016 Feb 21. Review. PubMed PMID: 26822889.
4: Petrovich IuA, Sukhova TV, Lemetskaia TI. [Use of mexidol in stomatology: results and perspectives]. Stomatologiia (Mosk). 2004;83(6):17-22. Review. Russian. PubMed PMID: 15609456.
5: Shishkova VN. [Specific features of neurological complications developing in patients with type 2 diabetes mellitus and metabolic syndrome: possibility for correction and prevention]. Ter Arkh. 2015;87(1):109-114. doi: 10.17116/terarkh2015871109-114. Review. Russian. PubMed PMID: 25823279.
6: Desiateryk VI, Mamchur DV. [Prophylaxis of hepatic insufficiency in patients with mechanical jaundice]. Klin Khir. 2014 Mar;(3):60-4. Review. Ukrainian. PubMed PMID: 25098004.
7: Lemetskaia TI, Ssukhova TV, Petrovich IuA. [Effect of mexidol on oral soft tissues in dental pathology]. Stomatologiia (Mosk). 2008;87(6):31-5. Review. Russian. PubMed PMID: 19209390.
8: Kispaeva TT. [Preventive/therapeutic correction of the development and progression of cognitive deficit in patients after stroke]. Zh Nevrol Psikhiatr Im S S Korsakova. 2013;113(7):76-9. Review. Russian. PubMed PMID: 24073453.
9: Shumyantseva VV, Bulko T, Shich E, Makhova A, Kuzikov A, Archakov A. Cytochrome p450 enzymes and electrochemistry: crosstalk with electrodes as redox partners and electron sources. Adv Exp Med Biol. 2015;851:229-46. doi: 10.1007/978-3-319-16009-2_9. Review. PubMed PMID: 26002738.
10: Chugunov AV, Kamchatnov PR, Mikhaĭlova NA. [Correction of free-radical oxidation as a pathogenetic approach to the treatment of acute ischemic stroke]. Zh Nevrol Psikhiatr Im S S Korsakova. 2009;109(10 Suppl 2):65-8. Review. Russian. PubMed PMID: 20229636.
11: Smirnov AV, Krivoruchko BI. [Antihypoxants in emergency medicine]. Anesteziol Reanimatol. 1998 Mar-Apr;(2):50-5. Review. Russian. PubMed PMID: 9612972.
12: Iasnetsov VV. [Protective effect of 3-hydroxypyridine derivatives in extreme conditions]. Aviakosm Ekolog Med. 2007 Nov-Dec;41(6):5-12. Review. Russian. PubMed PMID: 18350829.
13: Voronina TA. [The role of synaptic transmission in memory and neurodegeneration processes and effects of neurotropic preparations]. Eksp Klin Farmakol. 2003 Mar-Apr;66(2):10-4. Review. Russian. PubMed PMID: 12962041.
14: Aleksandrova AE. [Antihypoxant activity and mechanisms of action of some natural and synthetic compounds]. Eksp Klin Farmakol. 2005 Sep-Oct;68(5):72-8. Review. Russian. PubMed PMID: 16277217.
15: Voronina TA. [Hypoxia and memory. Specific features of nootropic agents effects and their use]. Vestn Ross Akad Med Nauk. 2000;(9):27-34. Review. Russian. PubMed PMID: 11055197.